



Orsiro[®] DES

BIOSTEMI trial

What would you choose for your heart?



Target Lesion Failure (TLF) rate at 24 months²



*BCI: Bayesian Credible Interval.

1. Posterior probability of superiority in STEMI in comparison to Xience at 24-months with respect to TLF, based on combined data set of BIOSTEMI and BIOSCIENCE STEMI groups; 2. Pilgrim et al. Biodegradable - versus durable-polymer drug-eluting stents for STEMI. Final 2-year outcomes of the BIOSTEMI trial. J Am Coll Cardiol. Cardiovasc Interven. 2021, doi: 10.1016/j.jcin.2020.12.011. For indications please see Instructions for Use.

Xience is a trademark or registered trademark of the Abbott Group of Companies. Orsiro is a trademark or registered trademark of the BIOTRONIK Group of Companies.